T1	SectionAnnotate 183 194	Impression:
T2	SectionSkip 7366 9883	Current Outpatient Medications   Medication Sig Dispense Refill    albuterol 90 mcg/actuation metered dose inhaler Inhale 2 puffs into the lungs every 4 (four) hours as needed.      AMBIEN CR 12.5 mg ER tablet nightly at bedtime.      brimonidine (MIRVASO) 0.33 % GEL Apply topically Daily.       cyclobenzaprine (FLEXERIL) 5 mg tablet Take 5 mg by mouth 3 (three) times daily as needed.      LORazepam (ATIVAN) 1 mg tablet Take 1 tablet (1 mg total) by 
 mouth every 6 (six) hours as needed for Anxiety. 30 tablet 3    morphine (MS CONTIN) 15 mg 12 hr ER tablet Take 15 mg by mouth Twice a day.      oxyCODONE (ROXICODONE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 8 (eight) hours as needed for Pain. 20 tablet 0    traMADol (ULTRAM) 50 mg tablet Take 1 tablet every 8 hours as needed for pain      acetaminophen (TYLENOL) 500 mg tablet Take 2 tablets (1,000 mg total) by mouth every 6 (six) hours. (Patient not taking: Reported on 02/22/2019) 60 tablet 0    esomeprazole (NEXIUM) 20 mg capsule Take 20 mg by mouth daily as needed.       LORazepam (ATIVAN) 0.5 mg tablet Take 0.5 mg by mouth every 12 (twelve) hours as needed.      naloxone 4 mg/actuation SPRAYNAERO Spray entire dose into 1 nostril for suspected overdose. If no response in 2-3 minutes, use new nasal spray for 2nd dose in other nostril.      polyethylene glycol (MIRALAX) 17 gram packet Take 1 packet (17 g total) by mouth daily as needed (constipation). (Patient not taking: Reported on 02/22/2019)      polyethylene glycol (MIRALAX) 17 gram packet Take 1 packet (17 g total) by mouth Daily. (Patient not taking: Reported on 03/17/2019) 510 g 11    prochlorperazine (COMPAZINE) 10 mg tablet Take 10 mg by mouth every 6 (six) hours as needed.      prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 03/17/2019) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth every morning. Starting in 1 week, 10/07/18. DO NOT TAKE THIS MEDICATION FROM *****/*****-*****/***** (Patient not taking: Reported on 03/17/2019)      simethicone (MYLICON) 80 mg chewable tablet Take 80 mg by mouth every 6 (six) hours as needed.      simethicone (MYLICON) 80 mg chewable tablet Take 1 tablet (80 mg total) by mouth every 4 (four) hours as needed for Flatulence. (Patient not taking: Reported on 
 03/17/2019) 100 tablet 2     No current facility-administered medications for this visit.
T3	SectionAnnotate 10725 10739	SOCIAL HISTORY
T4	SectionAnnotate 11973 11987	Social History
T6	SectionAnnotate 13310 13327	ASSESSMENT & PLAN
T7	PROBLEM 195 208	Metastatic ER
T9	MedicationName 250 264	nab paclitaxel
T10	TREATMENT 269 282	pembrolizumab
T11	DiseaseState 403 414	progression
T12	TreatmentType 451 470	chemo-immunotherapy
T13	PROBLEM 475 507	her MSI high  metastatic disease
T14	TEST 515 534	The imaging studies
T15	TEST 571 582	prior scans
T16	TEST 586 590	Labs
T17	TreatmentType 624 633	treatment
T18	TreatmentType 661 668	therapy
T19	DiseaseState 675 686	progression
T20	Symptom 690 714	intolerable side effects
T21	Radiology 716 723	Imaging
T22	Symptom 734 742	symptoms
T23	ClinicalCondition 929 943	Lynch syndrome
T24	PROBLEM 949 973	early stage colon cancer
T25	PROBLEM 978 996	endometrial cancer
T26	PROBLEM 1001 1060	newly diagnosed metastatic breast cancer to liver and nodes
T27	MedicationName 1074 1087	pembrolizumab
T28	MedicationName 1092 1100	abraxane
T30	TREATMENT 1199 1207	Prilosec
T31	Symptom 1240 1246	nausea
T32	MedicationName 1257 1263	ativan
T33	Symptom 1292 1299	fatigue
T34	TREATMENT 1317 1326	treatment
T35	PROBLEM 1343 1362	right axillary pain
T36	PROBLEM 1429 1451	right lumbosacral pain
T37	PROBLEM 1475 1506	new aching in her arms and legs
T38	MedicationName 1518 1526	flexeril
T39	TREATMENT 1531 1540	MS contin
T40	MedicationName 1552 1561	oxycodone
T41	PROBLEM 1582 1590	numbness
T42	PROBLEM 1591 1622	tingling in toes and fingertips
T43	PROBLEM 1659 1671	leg cramping
T44	TEST 1709 1722	recent biopsy
T45	PROBLEM 1738 1764	non-occlusive jugular clot
T46	Symptom 1804 1809	fever
T47	Symptom 1811 1817	chills
T48	Symptom 1819 1830	diaphoresis
T49	Symptom 1832 1847	appetite change
T50	Symptom 1849 1856	fatigue
T51	Symptom 1861 1885	unexpected weight change
T52	Symptom 1908 1920	hearing loss
T53	Symptom 1922 1932	nosebleeds
T54	Symptom 1936 1946	congestion
T55	Symptom 1948 1959	sore throat
T56	Symptom 1961 1972	mouth sores
T57	Symptom 1974 1983	neck pain
T58	Symptom 1985 1999	sinus pressure
T59	Symptom 2004 2012	tinnitus
T60	Symptom 2036 2047	photophobia
T61	Symptom 2049 2053	pain
T62	Symptom 2055 2064	discharge
T63	Symptom 2066 2073	redness
T64	Symptom 2075 2082	itching
T65	Symptom 2087 2105	visual disturbance
T66	Symptom 2135 2140	apnea
T67	Symptom 2142 2147	cough
T68	Symptom 2149 2164	chest tightness
T69	Symptom 2166 2185	shortness of breath
T70	Symptom 2187 2195	wheezing
T71	Symptom 2228 2238	chest pain
T72	Symptom 2240 2252	palpitations
T73	Symptom 2257 2269	leg swelling
T74	Symptom 2304 2310	nausea
T75	Symptom 2312 2320	vomiting
T76	Symptom 2322 2336	abdominal pain
T77	Symptom 2338 2346	diarrhea
T78	Symptom 2348 2360	constipation
T79	Symptom 2362 2376	blood in stool
T80	Symptom 2381 2401	abdominal distention
T81	Symptom 2433 2440	dysuria
T82	Symptom 2442 2449	urgency
T83	Symptom 2451 2460	frequency
T84	Symptom 2462 2471	hematuria
T85	Symptom 2473 2489	vaginal bleeding
T86	Symptom 2493 2502	discharge
T87	Symptom 2506 2526	difficulty urinating
T88	Symptom 2560 2568	myalgias
T89	Symptom 2570 2579	back pain
T90	Symptom 2581 2595	joint swelling
T91	Symptom 2600 2611	arthralgias
T92	Symptom 2634 2641	itching
T93	Symptom 2645 2649	rash
T94	Symptom 2680 2690	neuropathy
T95	Symptom 2692 2701	dizziness
T96	Symptom 2703 2710	tremors
T97	Symptom 2712 2720	seizures
T98	Symptom 2722 2729	syncope
T99	Symptom 2731 2748	speech difficulty
T100	Symptom 2750 2758	weakness
T101	Symptom 2760 2776	light-headedness
T102	Symptom 2778 2786	numbness
T103	Symptom 2791 2800	headaches
T104	Symptom 2832 2842	adenopathy
T105	Symptom 2853 2865	bruise/bleed
T106	Symptom 2913 2927	suicidal ideas
T107	Symptom 2929 2946	sleep disturbance
T108	Symptom 2948 2971	decreased concentration
T109	PROBLEM 3084 3098	Lynch syndrome
T110	PROBLEM 3114 3132	Colon cancer (HCC)
T111	PROBLEM 3148 3178	Metastatic breast cancer (HCC)
T112	PROBLEM 3194 3219	Early stage breast cancer
T113	PROBLEM 3226 3244	clinical Stage IIB
T114	TEST 3246 3257	cT2 cN1 cM0
T115	TEST 3264 3267	T1c
T116	TEST 3271 3276	ypN1a
T117	PROBLEM 3296 3337	triple negative invasive ductal carcinoma
T118	TREATMENT 3344 3360	neoadjuvant ddAC
T119	TREATMENT 3385 3407	carboplatin/paclitaxel
T120	PROBLEM 3429 3443	poor tolerance
T121	DiseaseState 3450 3469	disease progression
T122	TREATMENT 3479 3490	carboplatin
T123	TREATMENT 3491 3501	paclitaxel
T124	TREATMENT 3508 3526	partial mastectomy
T125	RadiationTherapyName 3550 3561	adjuvant RT
T127	ProcedureName 3638 3644	biopsy
T128	Histology 3666 3670	TNBC
T129	TEST 3674 3690	the R chest wall
T130	GenomicTest 3693 3708	Genetic testing
T131	TEST 3728 3744	the colon biopsy
T133	TEST 3784 3795	a pelvic US
T134	Symptom 3800 3804	pain
T135	PROBLEM 3823 3875	11mm EMS 2.4cm countor abnormality in the myometrium
T136	PROBLEM 3877 3911	1.4cm complex right 
 ovarian cyst
T137	PROBLEM 3913 3952	left 4.7cm septated cyst in left adnexa
T138	PROBLEM 3959 3971	hydrosalpinx
T139	ClinicalCondition 3984 3990	cancer
T140	ProcedureName 3992 3998	PET/CT
T141	TEST 4003 4021	complete restaging
T142	PROBLEM 4044 4062	distant metastases
T143	PROBLEM 4076 4098	a hypermetabolic focus
T144	PROBLEM 4165 4195	a primary colon adenocarcinoma
T145	PROBLEM 4201 4225	mucinous differentiation
T148	GenomicTest 4270 4295	Germline mutation testing
T149	PROBLEM 4309 4322	MSH2 mutation
T150	PROBLEM 4324 4344	Lynch syndrome panel
T151	PROBLEM 4377 4382	EPCAM
T152	PROBLEM 4384 4388	MLH1
T153	TREATMENT 4396 4400	MSH6
T154	TREATMENT 4406 4410	PMS2
T155	TEST 4426 4430	MSH2
T156	TEST 4465 4476	Colonoscopy
T157	PROBLEM 4500 4528	a 3cm descending colon polyp
T158	TREATMENT 4533 4544	polypectomy
T159	PROBLEM 4546 4574	primary colon adenocarcinoma
T160	Histology 4580 4597	mucinous features
T161	PROBLEM 4603 4615	loss of MSH2
T162	PROBLEM 4617 4621	MSH6
T163	TREATMENT 4629 4649	transverse colectomy
T164	PROBLEM 4666 4682	Stage I (pT2 pN0
T165	TreatmentType 4688 4700	chemotherapy
T166	RadiationTherapyName 4704 4713	radiation
T167	TEST 4718 4727	Brain MRI
T168	PROBLEM 4741 4751	metastases
T169	PROBLEM 4755 4769	Uterine cancer
T170	Radiology 4771 4777	PET/CT
T171	PROBLEM 4790 4832	some hypermetabolic activity in the uterus
T172	TEST 4837 4843	workup
T173	TEST 4858 4872	TVUS/pelvic US
T174	PROBLEM 4877 4891	uterine masses
T175	PROBLEM 4909 4932	hypermetabolic activity
T176	PROBLEM 4957 4978	cyst c/f hydrosalpinx
T177	PROBLEM 4993 5019	irregular vaginal bleeding
T178	TEST 5025 5043	endometrial biopsy
T179	TEST 5061 5070	pathology
T180	PROBLEM 5079 5126	well-differentiated endometrioid adenocarcinoma
T181	PROBLEM 5189 5223	R breast invasive ductal carcinoma
T182	TEST 5225 5237	ER-/PR-/Her2
T183	TEST 5261 5273	BRCA testing
T184	PROBLEM 5355 5374	Her2- breast cancer
T185	TEST 5398 5413	Genetic testing
T186	PROBLEM 5437 5441	BRCA
T187	TEST 5447 5450	ATM
T188	PROBLEM 5452 5456	CDH1
T189	TEST 5457 5462	CHEK2
T190	TEST 5464 5469	PALB2
T191	TEST 5471 5475	PTEN
T192	TEST 5477 5482	STK11
T193	TEST 5484 5488	TP53
T194	PROBLEM 5503 5565	Splenic flexure moderately differentiated colon adenocarcinoma
T195	PROBLEM 5574 5598	mucinous differentiation
T196	PROBLEM 5613 5617	MSH2
T197	PROBLEM 5619 5623	MSH6
T198	TEST 5629 5653	Final Surgical Pathology
T199	PROBLEM 5661 5709	poorly differentiated signet ring cell carcinoma
T200	TEST 5711 5714	TVA
T201	PROBLEM 5729 5749	high-grade dysplasia
T202	PROBLEM 5757 5777	Lynch syndrome panel
T203	PROBLEM 5810 5815	EPCAM
T204	PROBLEM 5817 5821	MLH1
T205	TREATMENT 5829 5833	MSH6
T206	TREATMENT 5839 5843	PMS2
T207	GenomicTestResult 5859 5863	MSH2
T208	TREATMENT 5872 5887	C (p.Ala636Pro)
T209	PROBLEM 5892 5919	Endometrioid adenocarcinoma
T210	TREATMENT 5981 6006	gemcitabine + carboplatin
T211	PROBLEM 6034 6054	pectoral lymph nodes
T212	PROBLEM 6058 6082	Metastatic breast cancer
T213	Radiology 6084 6090	PET/CT
T214	PROBLEM 6106 6151	Ill-defined right pectoralis soft tissue mass
T215	PROBLEM 6157 6180	internal calcifications
T216	TEST 6222 6235	a maximum SUV
T217	TEST 6248 6276	Right subpectoral lymph node
T218	TEST 6326 6337	maximum SUV
T219	PROBLEM 6350 6383	Hypoenhancing caudate lobe lesion
T220	TEST 6425 6438	a maximum SUV
T221	PROBLEM 6453 6483	Lytic S1 vertebral body lesion
T222	TEST 6485 6496	maximum SUV
T223	PROBLEM 6519 6530	Index nodes
T224	PROBLEM 6551 6604	Additional hypermetabolic right internal mammary node
T225	TEST 6647 6660	a maximum SUV
T226	PROBLEM 6670 6708	The hypermetabolic caudate lobe lesion
T227	TEST 6756 6779	prior CT abdomen/pelvis
T228	PROBLEM 6797 6858	Additional hypoattenuating, hypermetabolic segment VII lesion
T229	TEST 6887 6900	a maximum SUV
T230	TEST 6919 6931	Liver biopsy
T231	PROBLEM 6933 6973	triple negative metastatic breast cancer
T232	PROBLEM 6980 6996	Vaginal bleeding
T233	PROBLEM 7012 7040	DVT (deep venous thrombosis)
T234	TEST 7042 7045	HCC
T235	PROBLEM 7062 7081	Left Subclavian DVT
T236	TEST 7102 7111	Dye study
T237	PROBLEM 7125 7171	complete occlusion of the brachiocephalic vein
T238	TREATMENT 7182 7198	Mediport removal
T239	TREATMENT 7214 7225	rivaroxaban
T240	PROBLEM 7249 7276	Endometrial carcinoma (HCC)
T241	TREATMENT 7329 7336	surgery
T242	TREATMENT 7353 7364	MEDICATIONS
T243	TREATMENT 7385 7409	Medications   Medication
T244	TREATMENT 7434 7443	albuterol
T245	TREATMENT 7550 7559	AMBIEN CR
T246	TREATMENT 7604 7625	brimonidine (MIRVASO)
T247	TREATMENT 7667 7693	cyclobenzaprine (FLEXERIL)
T248	TREATMENT 7764 7782	LORazepam (ATIVAN)
T249	PROBLEM 7867 7874	Anxiety
T250	TREATMENT 7892 7912	morphine (MS CONTIN)
T251	TREATMENT 7974 7996	oxyCODONE (ROXICODONE)
T252	PROBLEM 8081 8085	Pain
T253	TREATMENT 8103 8120	traMADol (ULTRAM)
T254	PROBLEM 8176 8180	pain
T255	TREATMENT 8187 8210	acetaminophen (TYLENOL)
T256	TREATMENT 8348 8369	esomeprazole (NEXIUM)
T257	TREATMENT 8428 8446	LORazepam (ATIVAN)
T258	TREATMENT 8523 8531	naloxone
T259	PROBLEM 8595 8613	suspected overdose
T260	TREATMENT 8650 8665	new nasal spray
T261	TREATMENT 8670 8695	2nd dose in other nostril
T262	TREATMENT 8703 8732	polyethylene glycol (MIRALAX)
T263	PROBLEM 8801 8813	constipation
T264	TREATMENT 8867 8896	polyethylene glycol (MIRALAX)
T265	TREATMENT 9013 9041	prochlorperazine (COMPAZINE)
T266	TREATMENT 9112 9140	prochlorperazine (COMPAZINE)
T267	PROBLEM 9222 9228	nausea
T268	PROBLEM 9233 9241	vomiting
T269	TREATMENT 9305 9326	rivaroxaban (XARELTO)
T270	TREATMENT 9530 9551	simethicone (MYLICON)
T271	TREATMENT 9631 9652	simethicone (MYLICON)
T272	PROBLEM 9747 9757	Flatulence
T273	TREATMENT 9856 9867	medications
T274	PROBLEM 9891 9911	ALLERGIES  Allergies
T275	TREATMENT 9932 9950	Allergen Reactions
T276	TREATMENT 9955 9966	Penicillins
T277	PROBLEM 9967 9978	Anaphylaxis
T278	PROBLEM 9993 10000	itching
T279	PROBLEM 10008 10013	Puffy
T280	PROBLEM 10018 10025	itching
T281	PROBLEM 10086 10090	Rash
T282	PROBLEM 10095 10117	Haemophilus Influenzae
T283	PROBLEM 10150 10154	H1N1
T284	PROBLEM 10170 10194	injection site itchiness
T285	PROBLEM 10213 10237	injection site itchiness
T286	TREATMENT 10247 10266	Hydrochlorothiazide
T287	PROBLEM 10291 10299	Swelling
T288	PROBLEM 10347 10351	Rash
T289	PROBLEM 10371 10393	a total body skin rash
T290	PROBLEM 10399 10404	hives
T291	TREATMENT 10413 10423	prednisone
T292	PROBLEM 10489 10511	a total body skin rash
T293	PROBLEM 10517 10522	hives
T294	TREATMENT 10531 10541	prednisone
T295	TREATMENT 10594 10603	Ibuprofen
T296	PROBLEM 10628 10636	Swelling
T297	PROBLEM 10653 10664	elevated BP
T298	PROBLEM 10784 10790	Asthma
T299	TREATMENT 10813 10824	her inhaler
T300	PROBLEM 10832 10854	Bipolar disorder (HCC)
T301	PROBLEM 10860 10879	Breast cancer (HCC)
T302	PROBLEM 10885 10895	Depression
T303	PROBLEM 10901 10929	DVT (deep venous thrombosis)
T304	PROBLEM 10931 10935	HCC)
T305	PROBLEM 10957 10968	Hepatitis C
T306	TREATMENT 11009 11021	chemotherapy
T307	PROBLEM 11027 11039	Hypertension
T308	TREATMENT 11051 11059	any meds
T309	TEST 11075 11077	bp
T310	PROBLEM 11217 11225	Leukemia
T311	TREATMENT 11285 11313	Mother          hysterectomy
T312	PROBLEM 11336 11355	s/p lacerated liver
T313	TREATMENT 11360 11376	liver transplant
T314	PROBLEM 11385 11399	Known Problems
T315	PROBLEM 11473 11487	Known Problems
T316	PROBLEM 11563 11577	Known Problems
T317	PROBLEM 11599 11611	Colon cancer
T318	PROBLEM 11657 11669	mets to lung
T319	PROBLEM 11688 11702	Uterine cancer
T320	PROBLEM 11730 11743	Breast cancer
T321	TEST 12343 12347	ECOG
T322	TEST 12351 12362	Vital Signs
T323	TEST 12365 12367	BP
T324	TEST 12378 12383	Pulse
T325	TEST 12390 12394	Temp
T326	TEST 12400 12401	C
T327	TEST 12421 12425	Resp
T328	TEST 12432 12434	Ht
T329	TEST 12478 12480	Wt
T330	TEST 12509 12512	LMP
T331	TEST 12527 12531	SpO2
T332	TEST 12539 12542	BMI
T333	PROBLEM 12579 12582	NAD
T334	PROBLEM 12607 12613	rashes
T335	PROBLEM 12617 12624	lesions
T336	PROBLEM 12640 12649	anicteric
T337	PROBLEM 12672 12689	sinuses nontender
T338	PROBLEM 12728 12736	erythema
T339	PROBLEM 12741 12747	thrush
T340	PROBLEM 12767 12821	cervical, supraclavicular, or axillary lymphadenopathy
T341	TEST 12865 12875	percussion
T342	PROBLEM 12880 12887	wheezes
T343	PROBLEM 12889 12896	rhonchi
T344	PROBLEM 12901 12909	crackles
T345	PROBLEM 12964 12971	murmurs
T346	PROBLEM 12976 12981	edema
T347	PROBLEM 12994 13000	masses
T348	PROBLEM 13033 13042	nontender
T349	PROBLEM 13047 13057	distention
T350	PROBLEM 13062 13074	organomegaly
T351	PROBLEM 13097 13134	point tenderness over bones or joints
T352	PROBLEM 13174 13205	focal motor or sensory deficits
T353	PROBLEM 13366 13380	Lynch syndrome
T354	PROBLEM 13386 13410	early stage colon cancer
T355	PROBLEM 13415 13433	endometrial cancer
T356	PROBLEM 13438 13497	newly diagnosed metastatic breast cancer to liver and nodes
T357	TREATMENT 13511 13524	pembrolizumab
T358	TREATMENT 13529 13537	abraxane
T359	PROBLEM 13591 13615	Metastatic breast cancer
T360	PROBLEM 13619 13632	axillary pain
T361	TREATMENT 13702 13710	abraxane
T362	TREATMENT 13739 13752	Pembrolizumab
T363	TEST 13776 13779	TSH
T364	TREATMENT 13827 13833	a port
T365	ClinicalCondition 13873 13885	Jugular clot
T366	TREATMENT 13897 13904	xarelto
T367	TREATMENT 13915 13929	port placement
T368	ClinicalCondition 13940 13952	Colon cancer
T369	PROBLEM 13956 13974	Endometrial cancer
T370	PROBLEM 13978 13984	Nausea
T371	PROBLEM 13985 13989	GERD
T372	TREATMENT 13997 14002	chemo
T373	TREATMENT 14015 14021	ativan
T374	TREATMENT 14026 14035	compazine
T375	PROBLEM 14041 14049	Allergic
T376	TREATMENT 14053 14059	zofran
T377	MedicationName 14066 14074	prilosec
T378	Symptom 14086 14107	Peripheral neuropathy
T379	MedicationName 14115 14121	Taxane
T380	PROBLEM 14123 14158	new and mild  - Monitor    Mylagias
T381	TREATMENT 14166 14172	Taxane
T382	TREATMENT 14176 14188	Rx mag oxide
T383	PROBLEM 14202 14206	Pain
T384	TREATMENT 14229 14238	pain mgmt
T385	TREATMENT 14251 14260	MS Contin
T386	TREATMENT 14271 14280	oxycodone
T387	TREATMENT 14286 14294	flexeril
T388	TREATMENT 14300 14306	ativan
T389	TREATMENT 14319 14333	stool softener
T390	PROBLEM 14345 14372	opioid induced constipation
T391	TREATMENT 14476 14487	medications
T392	TREATMENT 14648 14666	the treatment plan
T393	PROBLEM 14668 14676	symptoms
T394	TREATMENT 14681 14700	therapeutic options
T395	Metastasis 195 205	Metastatic
A1	NegationModalityVal T395 affirmed
A2	HistoryVal T395 history
A3	EpisodeDescription T395 FirstOccurrence
T396	BiomarkerName 206 208	ER
T397	BiomarkerResult 209 217	negative
A4	BiomarkerResultVal T397 Negative
*	BiomarkerRel T396 T397
T398	BiomarkerName 219 223	HER2
T399	BiomarkerResult 224 232	negative
A5	BiomarkerResultVal T399 Negative
*	BiomarkerRel T398 T399
A6	NegationModalityVal T9 affirmed
A7	TreatmentContinuityVal T9 continuing
A8	TreatmentTypeVal T9 maintenance
A9	TreatmentIntentVal T9 palliative
T400	MedicationName 269 282	pembrolizumab
A10	TreatmentContinuityVal T400 continuing
A11	TreatmentTypeVal T400 maintenance
A12	TreatmentIntentVal T400 palliative
A13	TreatmentCategory T400 AntiNeoPlastics
A14	NegationModalityVal T11 affirmed
A15	NegationModalityVal T12 planned_in_future
A16	TreatmentTypeVal T12 maintenance
T401	Histology 479 482	MSI
A17	NegationModalityVal T401 affirmed
A18	HistoryVal T401 history
A19	EpisodeDescription T401 FirstOccurrence
R3	TreatmentAdministeredForProblem Treatment:T12 Prob:T401	
T402	Metastasis 489 499	metastatic
A20	HistoryVal T402 history
A21	EpisodeDescription T402 FirstOccurrence
A22	NegationModalityVal T17 affirmed
A23	TreatmentTypeVal T17 maintenance
A24	NegationModalityVal T18 affirmed
A25	TreatmentTypeVal T18 maintenance
A26	NegationModalityVal T19 hypothetical_in_future
A27	NegationModalityVal T20 hypothetical_in_future
A28	ChronicVal T20 non-chronic
R4	TreatmentDiscontinuedBecauseOf Therapy:T18 Reason:T20	
A29	NegationModalityVal T21 hypothetical_in_future
A30	NegationModalityVal T22 hypothetical_in_future
A31	ChronicVal T23 chronic
A32	ContinuityVal T23 stable
A33	ExperiencerVal T23 patient
T403	Stage 949 954	early
T404	ClinicalCondition 967 973	cancer
A34	ChronicVal T404 chronic
A35	ContinuityVal T404 stable
T405	ClinicalCondition 990 996	cancer
A36	NegationModalityVal T405 affirmed
A37	ChronicVal T405 chronic
A38	ContinuityVal T405 stable
T407	Metastasis 1017 1027	metastatic
A41	HistoryVal T407 new
A42	EpisodeDescription T407 FirstOccurrence
T408	Site 1045 1050	liver
T409	Site 1055 1060	nodes
R5	SiteOf Arg1:T408 Arg2:T407	
R6	SiteOf Arg1:T409 Arg2:T407	
A43	NegationModalityVal T27 affirmed
A44	TreatmentContinuityVal T27 continuing
A45	TreatmentTypeVal T27 maintenance
A46	TreatmentIntentVal T27 palliative
A47	TreatmentCategory T27 AntiNeoPlastics
A48	NegationModalityVal T28 affirmed
A49	TreatmentContinuityVal T28 continuing
A50	TreatmentTypeVal T28 maintenance
A51	TreatmentIntentVal T28 palliative
A52	TreatmentCategory T28 AntiNeoPlastics
T410	Datetime 1104 1112	03/11/19
T411	Cycles 1142 1143	1
T29	Symptom 1193 1197	GERD
A54	IsPresentOnFirstCancerDiagnosis T29 unclear
A55	IsCausedByDiagnosedCancer T29 no
A56	ContinuityVal T29 worsening
A57	NegationModalityVal T31 affirmed
A58	IsPresentOnFirstCancerDiagnosis T31 no
A59	IsCausedByDiagnosedCancer T31 no
A60	ChronicVal T31 non-chronic
A61	ContinuityVal T31 stable
A62	TreatmentCategory T32 Supportive
R7	TreatmentAdministeredForProblem Treatment:T32 Prob:T31	
A63	IsPresentOnFirstCancerDiagnosis T33 no
A64	IsCausedByDiagnosedCancer T33 no
A65	ChronicVal T33 non-chronic
A66	ContinuityVal T33 stable
T412	TreatmentType 1317 1326	treatment
A67	NegationModalityVal T412 affirmed
A68	TreatmentTypeVal T412 maintenance
R8	ConditionOrTreatmentCausesProblem Treatment:T412 Prob:T33	
T413	Symptom 1358 1362	pain
A69	NegationModalityVal T413 affirmed
A70	ChronicVal T413 non-chronic
A71	ContinuityVal T413 improving
T414	Site 1349 1357	axillary
T415	Laterality 1343 1348	right
R9	LateralityOfSite Arg1:T415 Arg2:T414	
R10	SiteOf Arg1:T414 Arg2:T413	
T416	Site 1366 1380	shoulder blade
T417	Laterality 1388 1393	right
R11	LateralityOfSite Arg1:T417 Arg2:T416	
R12	SiteOf Arg1:T416 Arg2:T413	
T418	Datetime 1413 1422	last week
T419	Symptom 1447 1451	pain
A73	IsPresentOnFirstCancerDiagnosis T419 no
A74	IsCausedByDiagnosedCancer T419 no
A75	ChronicVal T419 non-chronic
A76	ContinuityVal T419 stable
T420	Site 1435 1446	lumbosacral
T421	Laterality 1429 1434	right
R13	LateralityOfSite Arg1:T421 Arg2:T420	
R14	SiteOf Arg1:T420 Arg2:T419	
T422	Symptom 1479 1485	aching
A77	IsPresentOnFirstCancerDiagnosis T422 no
A78	IsCausedByDiagnosedCancer T422 no
A79	ChronicVal T422 non-chronic
A80	ContinuityVal T422 new
T423	Site 1493 1497	arms
T424	Site 1502 1506	legs
R15	SiteOf Arg1:T423 Arg2:T422	
R16	SiteOf Arg1:T424 Arg2:T422	
A81	TreatmentCategory T38 Supportive
T425	MedicationName 1531 1540	MS contin
A82	TreatmentCategory T425 Supportive
A83	TreatmentCategory T40 Supportive
T426	Symptom 1582 1590	numbness
A84	NegationModalityVal T426 affirmed
A85	IsPresentOnFirstCancerDiagnosis T426 no
A86	IsCausedByDiagnosedCancer T426 no
A87	ChronicVal T426 non-chronic
A88	ContinuityVal T426 stable
T427	Symptom 1591 1599	tingling
A89	IsPresentOnFirstCancerDiagnosis T427 no
A90	IsCausedByDiagnosedCancer T427 no
A91	ChronicVal T427 non-chronic
A92	ContinuityVal T427 stable
T428	Site 1603 1607	toes
T429	Site 1612 1622	fingertips
R17	SiteOf Arg1:T428 Arg2:T426	
R18	SiteOf Arg1:T428 Arg2:T427	
R20	SiteOf Arg1:T429 Arg2:T427	
R19	SiteOf Arg1:T429 Arg2:T426	
R21	SiteOf Arg1:T428 Arg2:T426	
T430	Symptom 1663 1671	cramping
A93	IsPresentOnFirstCancerDiagnosis T430 no
A94	IsCausedByDiagnosedCancer T430 no
A95	ChronicVal T430 non-chronic
A96	ContinuityVal T430 stable
T431	Site 1659 1662	leg
R22	SiteOf Arg1:T431 Arg2:T430	
R23	ConditionOrTreatmentCausesProblem Treatment:T28 Prob:T426	
R24	ConditionOrTreatmentCausesProblem Treatment:T28 Prob:T427	
A97	NegationModalityVal T46 negated
A98	NegationModalityVal T47 negated
A99	NegationModalityVal T48 negated
A100	NegationModalityVal T49 negated
A101	NegationModalityVal T50 negated
A102	NegationModalityVal T51 negated
A103	NegationModalityVal T52 negated
A104	NegationModalityVal T53 negated
A105	NegationModalityVal T54 negated
A106	NegationModalityVal T55 negated
A107	NegationModalityVal T56 negated
A108	NegationModalityVal T57 negated
A109	NegationModalityVal T58 negated
A110	NegationModalityVal T59 negated
A111	NegationModalityVal T60 negated
A112	NegationModalityVal T61 negated
A113	NegationModalityVal T62 negated
A114	NegationModalityVal T63 negated
A115	NegationModalityVal T64 negated
A116	NegationModalityVal T65 negated
A117	NegationModalityVal T66 negated
A118	NegationModalityVal T67 negated
A119	NegationModalityVal T68 negated
A120	NegationModalityVal T69 negated
A121	NegationModalityVal T70 negated
A122	NegationModalityVal T71 negated
A123	NegationModalityVal T72 negated
A124	NegationModalityVal T73 negated
A125	NegationModalityVal T74 negated
A126	NegationModalityVal T75 negated
A127	NegationModalityVal T76 negated
A128	NegationModalityVal T77 negated
A129	NegationModalityVal T78 negated
A130	NegationModalityVal T79 negated
A131	NegationModalityVal T80 negated
A132	NegationModalityVal T81 negated
A133	NegationModalityVal T82 negated
A134	NegationModalityVal T83 negated
A135	NegationModalityVal T84 negated
A136	NegationModalityVal T85 negated
A137	NegationModalityVal T86 negated
A138	NegationModalityVal T87 negated
A139	NegationModalityVal T88 negated
A140	NegationModalityVal T89 negated
A141	NegationModalityVal T90 negated
A142	NegationModalityVal T91 negated
A143	NegationModalityVal T92 negated
A144	NegationModalityVal T93 negated
A145	NegationModalityVal T94 negated
A146	NegationModalityVal T95 negated
A147	NegationModalityVal T96 negated
A148	NegationModalityVal T97 negated
A149	NegationModalityVal T98 negated
A150	NegationModalityVal T99 negated
A151	NegationModalityVal T100 negated
A152	NegationModalityVal T103 negated
A153	NegationModalityVal T104 negated
A154	NegationModalityVal T105 negated
A155	NegationModalityVal T106 negated
A156	NegationModalityVal T107 negated
A157	NegationModalityVal T108 negated
T433	Stage 3194 3199	Early
T434	Datetime 3220 3224	2014
T435	Stage 3241 3244	IIB
T436	TNM 3246 3257	cT2 cN1 cM0
A159	NegationModalityVal T436 affirmed
A160	HistoryVal T436 history
T437	TNM 3262 3276	ypT1c(m) ypN1a
T438	LymphNodeInvolvement 3278 3282	1/22
A161	NegationModalityVal T438 affirmed
A162	EpisodeDescription T438 FirstOccurrence
T440	Histology 3312 3337	invasive ductal carcinoma
A165	HistoryVal T440 history
A166	EpisodeDescription T440 FirstOccurrence
T441	MedicationRegimen 3356 3360	ddAC
A167	NegationModalityVal T441 affirmed
A168	TreatmentTypeVal T441 neoadjuvant
A169	TreatmentIntentVal T441 curative
T442	MedicationRegimen 3385 3407	carboplatin/paclitaxel
A170	TreatmentContinuityVal T442 discontinued_early
A171	TreatmentTypeVal T442 neoadjuvant
A172	TreatmentIntentVal T442 curative
T443	Cycles 3363 3367	5/12
*	TreatmentDesc T443 T442
T444	Symptom 3429 3443	poor tolerance
A173	ChronicVal T444 non-chronic
A174	ContinuityVal T444 stopped
R25	ConditionOrTreatmentCausesProblem Treatment:T442 Prob:T444	
T445	MedicationRegimen 3479 3501	carboplatin/paclitaxel
A175	TreatmentContinuityVal T445 discontinued_early
T446	ProcedureName 3508 3526	partial mastectomy
A176	IntentVal T446 treatment-curative
A177	TreatmentTypeVal T446 local
A178	IsTumorRemaining T446 unclear
T447	Datetime 3530 3543	February 2014
A179	TreatmentContinuityVal T125 finished
A180	TreatmentTypeVal T125 local
A181	TreatmentIntentVal T125 curative
T448	DiseaseState 3604 3620	local recurrence
T449	Datetime 3621 3625	2018
T450	Datetime 3627 3637	March 2018
A182	IntentVal T127 diagnosis
A183	HistoryVal T128 history
A184	EpisodeDescription T128 Progression
R26	TestOrProcedureReveals Test:T127 Desc:T128	
T451	Site 3680 3690	chest wall
T452	Laterality 3678 3679	R
R27	LateralityOfSite Arg1:T452 Arg2:T451	
R28	SiteOf Arg1:T451 Arg2:T128	
T132	GenomicTestResult 3762 3770	BRCA 1/2
A185	NegationModalityVal T132 negated
T453	Radiology 3793 3795	US
A186	IntentVal T453 diagnosis
A187	IsPresentOnFirstCancerDiagnosis T134 no
A188	IsCausedByDiagnosedCancer T134 yes
A189	ChronicVal T134 non-chronic
A190	ContinuityVal T134 new
R29	TestOrProcedureConductedForProblem Test:T453 Prob:T134	
T454	Datetime 3805 3813	04/01/18
T455	Size 3832 3837	2.4cm
T456	Size 3877 3882	1.4cm
T457	Size 3918 3923	4.7cm
T458	RadPathResult 3924 3937	septated cyst
A191	RadPathResultVal T458 Unclear
T459	Site 3946 3952	adnexa
T460	Laterality 3941 3945	left
R30	LateralityOfSite Arg1:T460 Arg2:T459	
R31	SiteOf Arg1:T459 Arg2:T458	
T461	RadPathResult 3959 3971	hydrosalpinx
A192	RadPathResultVal T461 Unclear
R32	ResultOfTest Desc:T461 Test:T453	
R33	ResultOfTest Desc:T458 Test:T453	
T462	RadPathResult 3838 3857	countor abnormality
A193	RadPathResultVal T462 Unclear
R34	ResultOfTest Desc:T462 Test:T453	
T463	Site 3865 3875	myometrium
R35	SiteOf Arg1:T463 Arg2:T462	
T464	RadPathResult 3899 3911	ovarian cyst
A194	RadPathResultVal T464 Unclear
R36	ResultOfTest Desc:T464 Test:T453	
T465	Site 3891 3896	right
A195	IntentVal T140 staging
T466	Metastasis 4052 4062	metastases
A196	NegationModalityVal T466 negated
R37	TestOrProcedureReveals Test:T140 Desc:T466	
T467	RadPathResult 4078 4098	hypermetabolic focus
A197	RadPathResultVal T467 Unclear
T468	Site 4106 4121	splenic flexure
R38	SiteOf Arg1:T468 Arg2:T467	
T469	Datetime 4145 4153	05/25/18
T470	ProcedureName 4133 4141	biopsied
A198	IntentVal T470 diagnosis
T471	ClinicalCondition 4167 4195	primary colon adenocarcinoma
A199	ChronicVal T471 non-chronic
A200	ContinuityVal T471 stable
R39	TestOrProcedureReveals Test:T140 Desc:T471	
T472	Histology 4201 4225	mucinous differentiation
A201	ChronicVal T139 chronic
T473	DiagnosticLabTest 4263 4266	IHC
A202	ExperiencerVal T148 patient
T474	GenomicTestResult 4309 4322	MSH2 mutation
T475	GenomicTestResult 4426 4454	MSH2 c.1906G>C (p.Ala636Pro)
A203	NegationModalityVal T475 affirmed
A204	ExperiencerVal T475 patient
T476	Datetime 4456 4464	05/25/18
T477	ProcedureName 4465 4476	Colonoscopy
A205	IntentVal T477 diagnosis
T478	Size 4502 4505	3cm
A206	HistoryVal T478 new
A207	EpisodeDescription T478 FirstOccurrence
T479	Site 4506 4522	descending colon
R42	SiteOf Arg1:T479 Arg2:T478	
R43	TestOrProcedureReveals Test:T477 Desc:T478	
T480	ProcedureName 4533 4544	polypectomy
A208	IntentVal T480 treatment-curative
A209	TreatmentTypeVal T480 local
A210	IsTumorRemaining T480 no
T481	TumorCharacteristics 4523 4528	polyp
R44	TestOrProcedureConductedForProblem Test:T480 Prob:T481	
T482	ClinicalCondition 4560 4574	adenocarcinoma
R45	TestOrProcedureReveals Test:T480 Desc:T482	
R46	TestOrProcedureReveals Test:T480 Desc:T160	
T485	ProcedureName 4629 4649	transverse colectomy
A211	IntentVal T485 treatment-curative
A212	TreatmentTypeVal T485 local
A213	IsTumorRemaining T485 no
T486	Datetime 4653 4662	June 2018
T487	Stage 4672 4673	I
T488	TNM 4675 4682	pT2 pN0
A214	NegationModalityVal T165 negated
A215	TreatmentTypeVal T165 adjuvant
A216	NegationModalityVal T166 negated
A217	TreatmentTypeVal T166 local
A218	TreatmentIntentVal T166 curative
T489	Radiology 4724 4727	MRI
A219	IntentVal T489 diagnosis
T490	Metastasis 4741 4751	metastases
A220	NegationModalityVal T490 negated
R49	TestOrProcedureReveals Test:T489 Desc:T490	
T491	ClinicalCondition 4755 4769	Uterine cancer
A221	NegationModalityVal T491 affirmed
A222	IntentVal T170 diagnosis
R50	TestOrProcedureReveals Test:T170 Desc:T491	
T492	RadPathResult 4795 4818	hypermetabolic activity
A223	NegationModalityVal T492 affirmed
A224	RadPathResultVal T492 Unclear
T493	Site 4826 4832	uterus
R51	SiteOf Arg1:T493 Arg2:T492	
T494	Radiology 4870 4872	US
A225	IntentVal T494 diagnosis
T495	RadPathResult 4885 4891	masses
A226	NegationModalityVal T495 negated
T496	Site 4877 4884	uterine
R52	SiteOf Arg1:T496 Arg2:T495	
R53	SiteOf Arg1:T496 Arg2:T494	
T497	RadPathResult 4909 4932	hypermetabolic activity
A227	NegationModalityVal T497 affirmed
A228	RadPathResultVal T497 Unclear
T498	Symptom 5003 5019	vaginal bleeding
A229	IsPresentOnFirstCancerDiagnosis T498 no
A230	IsCausedByDiagnosedCancer T498 no
A231	ChronicVal T498 non-chronic
A232	ContinuityVal T498 new
T499	ProcedureName 5037 5043	biopsy
A233	IntentVal T499 diagnosis
T500	Site 5025 5036	endometrial
R54	SiteOf Arg1:T500 Arg2:T499	
R55	ConditionOrTreatmentCausesProblem Treatment:T499 Prob:T498	
T501	Datetime 5047 5055	06/30/18
T502	ClinicalCondition 5099 5126	endometrioid adenocarcinoma
A234	ChronicVal T502 non-chronic
A235	ContinuityVal T502 new
R56	TestOrProcedureReveals Test:T499 Desc:T502	
T503	Datetime 5178 5188	July 2013:
T504	Histology 5198 5223	invasive ductal carcinoma
A236	HistoryVal T504 new
A237	EpisodeDescription T504 FirstOccurrence
T505	Site 5191 5197	breast
T506	Laterality 5189 5190	R
R57	LateralityOfSite Arg1:T506 Arg2:T505	
R58	SiteOf Arg1:T505 Arg2:T504	
T507	BiomarkerName 5225 5227	ER
T508	BiomarkerName 5229 5231	PR
T509	BiomarkerName 5233 5237	Her2
T510	BiomarkerResult 5227 5228	-
A238	BiomarkerResultVal T510 Negative
T511	BiomarkerResult 5231 5232	-
A239	BiomarkerResultVal T511 Negative
T512	BiomarkerResult 5237 5238	-
A240	BiomarkerResultVal T512 Negative
*	BiomarkerRel T507 T510
*	BiomarkerRel T508 T511
*	BiomarkerRel T509 T512
T513	TumorCharacteristics 5240 5244	TNBC
A241	EpisodeDescription T513 FirstOccurrence
T514	Grade 5253 5254	3
T515	GenomicTest 5261 5273	BRCA testing
A242	NegationModalityVal T515 negated
T516	Datetime 5321 5331	March 2018
T517	DiseaseState 5333 5343	Recurrence
T518	BiomarkerName 5347 5349	ER
T519	BiomarkerName 5351 5353	PR
T520	BiomarkerName 5355 5359	Her2
T521	BiomarkerResult 5349 5350	-
A243	BiomarkerResultVal T521 Negative
T522	BiomarkerResult 5353 5354	-
A244	BiomarkerResultVal T522 Negative
T523	BiomarkerResult 5359 5360	-
A245	BiomarkerResultVal T523 Negative
*	BiomarkerRel T521 T518
*	BiomarkerRel T519 T522
*	BiomarkerRel T520 T523
T524	TumorCharacteristics 5368 5374	cancer
A246	EpisodeDescription T524 Recurrence
T525	Site 5380 5390	chest wall
T526	Laterality 5378 5379	R
R59	LateralityOfSite Arg1:T526 Arg2:T525	
R60	SiteOf Arg1:T525 Arg2:T524	
T527	Datetime 5414 5423	05/19/18:
T528	GenomicTestResult 5437 5445	BRCA 1/2
A247	NegationModalityVal T528 negated
T529	GenomicTestResult 5447 5450	ATM
A248	NegationModalityVal T529 negated
T530	GenomicTestResult 5452 5456	CDH1
A249	NegationModalityVal T530 negated
T531	GenomicTestResult 5457 5462	CHEK2
A250	NegationModalityVal T531 negated
T532	GenomicTestResult 5464 5469	PALB2
A251	NegationModalityVal T532 negated
T533	GenomicTestResult 5471 5475	PTEN
A252	NegationModalityVal T533 negated
T534	GenomicTestResult 5477 5482	STK11
A253	NegationModalityVal T534 negated
T535	GenomicTestResult 5484 5488	TP53
A254	NegationModalityVal T535 negated
T536	Datetime 5493 5501	May 2018
T537	ClinicalCondition 5551 5565	adenocarcinoma
A255	ChronicVal T537 non-chronic
A256	ContinuityVal T537 new
A257	ExperiencerVal T537 patient
T538	Histology 5519 5544	moderately differentiated
T539	Site 5503 5518	Splenic flexure
R61	SiteOf Arg1:T539 Arg2:T538	
R62	SiteOf Arg1:T539 Arg2:T537	
T540	Histology 5574 5598	mucinous differentiation
R63	SiteOf Arg1:T539 Arg2:T540	
T541	GenomicTestResult 5613 5617	MSH2
A258	NegationModalityVal T541 affirmed
T542	GenomicTestResult 5619 5623	MSH6
A259	NegationModalityVal T542 affirmed
R64	SiteOf Arg1:T539 Arg2:T541	
R65	SiteOf Arg1:T539 Arg2:T542	
T543	Pathology 5635 5653	Surgical Pathology
A260	IntentVal T543 diagnosis
T544	Histology 5683 5709	signet ring cell carcinoma
R66	TestOrProcedureReveals Test:T543 Desc:T544	
T545	Histology 5661 5682	poorly differentiated
R67	TestOrProcedureReveals Test:T543 Desc:T545	
T546	Histology 5729 5749	high-grade dysplasia
R68	TestOrProcedureReveals Test:T543 Desc:T546	
A261	NegationModalityVal T207 affirmed
T547	GenomicTestResult 5864 5887	c.1906G>C (p.Ala636Pro)
A262	NegationModalityVal T547 affirmed
T548	ClinicalCondition 5892 5919	Endometrioid adenocarcinoma
A263	ChronicVal T548 non-chronic
A264	ContinuityVal T548 new
A265	ExperiencerVal T548 patient
T550	MedicationRegimen 5981 6006	gemcitabine + carboplatin
A267	TreatmentContinuityVal T550 finished
A268	TreatmentTypeVal T550 others
A269	TreatmentIntentVal T550 others
T551	Site 6034 6054	pectoral lymph nodes
T552	ClinicalCondition 6076 6082	cancer
T553	Metastasis 6058 6068	Metastatic
A270	IntentVal T213 staging
T554	Datetime 6091 6099	01/27/19
T555	ClinicalCondition 13366 13380	Lynch syndrome
A271	ChronicVal T555 chronic
A272	ContinuityVal T555 stable
T556	ClinicalCondition 13398 13410	colon cancer
A273	ChronicVal T556 non-chronic
A274	ContinuityVal T556 stable
T557	Stage 13386 13391	early
T558	ClinicalCondition 13415 13433	endometrial cancer
A275	ChronicVal T558 non-chronic
A276	ContinuityVal T558 stable
A277	ExperiencerVal T558 patient
T560	Metastasis 13454 13464	metastatic
A280	NegationModalityVal T560 affirmed
A281	HistoryVal T560 new
A282	EpisodeDescription T560 FirstOccurrence
T561	Site 13482 13487	liver
T562	Site 13492 13497	nodes
R69	SiteOf Arg1:T561 Arg2:T560	
R70	SiteOf Arg1:T562 Arg2:T560	
T563	MedicationName 13511 13524	pembrolizumab
A283	TreatmentContinuityVal T563 continuing
A284	TreatmentTypeVal T563 maintenance
A285	TreatmentIntentVal T563 palliative
A286	TreatmentCategory T563 AntiNeoPlastics
T564	MedicationName 13529 13537	abraxane
A287	TreatmentTypeVal T564 maintenance
A288	TreatmentIntentVal T564 palliative
A289	TreatmentCategory T564 AntiNeoPlastics
T565	Datetime 13541 13549	03/11/19
T566	Cycles 13579 13580	1
T567	Symptom 13628 13632	pain
A291	IsPresentOnFirstCancerDiagnosis T567 unclear
A292	IsCausedByDiagnosedCancer T567 yes
A293	ChronicVal T567 non-chronic
A294	ContinuityVal T567 improving
T569	Metastasis 13591 13601	Metastatic
T570	MedicationName 13702 13710	abraxane
A295	TreatmentContinuityVal T570 continuing
A296	TreatmentTypeVal T570 maintenance
A297	TreatmentIntentVal T570 palliative
A298	TreatmentCategory T570 AntiNeoPlastics
T571	MedicationName 13739 13752	Pembrolizumab
A299	TreatmentTypeVal T571 maintenance
A300	TreatmentIntentVal T571 palliative
A301	TreatmentCategory T571 AntiNeoPlastics
A302	ChronicVal T365 non-chronic
A303	ContinuityVal T365 stable
A304	ChronicVal T368 non-chronic
A305	ContinuityVal T368 stable
T572	ClinicalCondition 13956 13974	Endometrial cancer
A306	ChronicVal T572 non-chronic
A307	ContinuityVal T572 stable
T573	TreatmentType 13997 14002	chemo
A308	TreatmentTypeVal T573 maintenance
T574	Symptom 13978 13984	Nausea
A309	IsPresentOnFirstCancerDiagnosis T574 no
A310	IsCausedByDiagnosedCancer T574 no
A311	ChronicVal T574 non-chronic
A312	ContinuityVal T574 stable
R71	ConditionOrTreatmentCausesProblem Treatment:T573 Prob:T574	
T575	Symptom 13985 13989	GERD
A313	IsPresentOnFirstCancerDiagnosis T575 no
A314	IsCausedByDiagnosedCancer T575 no
A315	ChronicVal T575 non-chronic
A316	ContinuityVal T575 stable
R72	ConditionOrTreatmentCausesProblem Treatment:T573 Prob:T575	
T576	MedicationName 14015 14021	ativan
A317	TreatmentCategory T576 Supportive
T577	MedicationName 14026 14035	compazine
A318	TreatmentCategory T577 Supportive
R73	TreatmentAdministeredForProblem Treatment:T576 Prob:T574	
R74	TreatmentAdministeredForProblem Treatment:T577 Prob:T574	
A319	TreatmentCategory T377 Supportive
R75	TreatmentAdministeredForProblem Treatment:T377 Prob:T575	
A320	IsPresentOnFirstCancerDiagnosis T378 no
A321	IsCausedByDiagnosedCancer T378 no
A322	ChronicVal T378 non-chronic
A323	ContinuityVal T378 new
A324	TreatmentContinuityVal T379 continuing
A325	TreatmentTypeVal T379 maintenance
A326	TreatmentIntentVal T379 palliative
A327	TreatmentCategory T379 AntiNeoPlastics
R76	ConditionOrTreatmentCausesProblem Treatment:T379 Prob:T378	
T578	MedicationName 14166 14172	Taxane
A328	TreatmentTypeVal T578 maintenance
A329	TreatmentIntentVal T578 palliative
A330	TreatmentCategory T578 AntiNeoPlastics
T579	Symptom 14150 14158	Mylagias
A331	NegationModalityVal T579 hypothetical_in_future
R77	ConditionOrTreatmentCausesProblem Treatment:T578 Prob:T579	
T580	MedicationName 14251 14260	MS Contin
A332	TreatmentCategory T580 Supportive
T581	MedicationName 14271 14280	oxycodone
A333	TreatmentCategory T581 Supportive
T582	MedicationName 14286 14294	flexeril
A334	TreatmentCategory T582 Supportive
T583	MedicationName 14300 14306	ativan
A335	TreatmentCategory T583 Supportive
T584	Symptom 14345 14372	opioid induced constipation
A336	NegationModalityVal T584 hypothetical_in_future
R78	ConditionOrTreatmentCausesProblem Treatment:T581 Prob:T584	
R79	ConditionOrTreatmentCausesProblem Treatment:T580 Prob:T584	
R80	BeginsOnOrAt Arg1:T564 Arg2:T565	
R81	TreatmentDesc Therapy:T564 Desc:T566	
R82	EndsOnOrAt Arg1:T413 Arg2:T418	
R83	BeginsOnOrAt Arg1:T28 Arg2:T410	
R84	BeginsOnOrAt Arg1:T27 Arg2:T410	
R85	TreatmentDesc Therapy:T27 Desc:T411	
R86	TreatmentDesc Therapy:T28 Desc:T411	
T585	Datetime 3179 3189	02/22/2019
R88	HappensAtOnDuring Arg1:T446 Arg2:T447	
R89	HappensAtOnDuring Arg1:T448 Arg2:T449	
R90	HappensAtOnDuring Arg1:T127 Arg2:T450	
R91	HappensAtOnDuring Arg1:T453 Arg2:T454	
R92	HappensAtOnDuring Arg1:T470 Arg2:T469	
R93	HappensAtOnDuring Arg1:T477 Arg2:T476	
R94	HappensAtOnDuring Arg1:T485 Arg2:T486	
R95	TestOrProcedureReveals Test:T485 Desc:T488	
R96	TestOrProcedureReveals Test:T485 Desc:T487	
R97	HappensAtOnDuring Arg1:T499 Arg2:T501	
R98	HappensAtOnDuring Arg1:T517 Arg2:T516	
T586	Insurance 5291 5300	insurance
R99	NotUndergoneBecauseOf Arg1:T515 Reason:T586	
R100	HappensAtOnDuring Arg1:T537 Arg2:T536	
A53	GenomicTestType T515 Germline
T587	GenomicTest 5398 5413	Genetic testing
R101	HappensAtOnDuring Arg1:T587 Arg2:T527	
R103	HappensAtOnDuring Arg1:T213 Arg2:T554	
T588	SectionSkip 9891 10695	ALLERGIES  Allergies/Contraindications   Allergen Reactions    Penicillins Anaphylaxis     Puffy and itching,       Puffy and itching,           Adhesive Tape-Silicones      Other reaction(s): Rash    Haemophilus Influenzae      Other reaction(s): Unknown H1N1  Get puffy and injection site itchiness     Get puffy and injection site itchiness         Hydrochlorothiazide      Other reaction(s): Swelling    Hydroxychloroquine      Other reaction(s): Rash  Pt states she got a total body skin rash with hives needing prednisone to resolve and was told to stop taking it      Pt states she got a total body skin rash with hives needing prednisone to resolve and was told to stop taking it          Ibuprofen      Other reaction(s): Swelling  As per patient elevated BP     As per patient elevated BP
A72	SectionSkipType T588 allergies
T589	SectionSkip 7353 7824;7827 9791;9794 9883	MEDICATIONS  Current Outpatient Medications   Medication Sig Dispense Refill    albuterol 90 mcg/actuation metered dose inhaler Inhale 2 puffs into the lungs every 4 (four) hours as needed.      AMBIEN CR 12.5 mg ER tablet nightly at bedtime.      brimonidine (MIRVASO) 0.33 % GEL Apply topically Daily.       cyclobenzaprine (FLEXERIL) 5 mg tablet Take 5 mg by mouth 3 (three) times daily as needed.      LORazepam (ATIVAN) 1 mg tablet Take 1 tablet (1 mg total) by mouth every 6 (six) hours as needed for Anxiety. 30 tablet 3    morphine (MS CONTIN) 15 mg 12 hr ER tablet Take 15 mg by mouth Twice a day.      oxyCODONE (ROXICODONE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 8 (eight) hours as needed for Pain. 20 tablet 0    traMADol (ULTRAM) 50 mg tablet Take 1 tablet every 8 hours as needed for pain      acetaminophen (TYLENOL) 500 mg tablet Take 2 tablets (1,000 mg total) by mouth every 6 (six) hours. (Patient not taking: Reported on 02/22/2019) 60 tablet 0    esomeprazole (NEXIUM) 20 mg capsule Take 20 mg by mouth daily as needed.       LORazepam (ATIVAN) 0.5 mg tablet Take 0.5 mg by mouth every 12 (twelve) hours as needed.      naloxone 4 mg/actuation SPRAYNAERO Spray entire dose into 1 nostril for suspected overdose. If no response in 2-3 minutes, use new nasal spray for 2nd dose in other nostril.      polyethylene glycol (MIRALAX) 17 gram packet Take 1 packet (17 g total) by mouth daily as needed (constipation). (Patient not taking: Reported on 02/22/2019)      polyethylene glycol (MIRALAX) 17 gram packet Take 1 packet (17 g total) by mouth Daily. (Patient not taking: Reported on 03/17/2019) 510 g 11    prochlorperazine (COMPAZINE) 10 mg tablet Take 10 mg by mouth every 6 (six) hours as needed.      prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 03/17/2019) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth every morning. Starting in 1 week, 10/07/18. DO NOT TAKE THIS MEDICATION FROM *****/*****-*****/***** (Patient not taking: Reported on 03/17/2019)      simethicone (MYLICON) 80 mg chewable tablet Take 80 mg by mouth every 6 (six) hours as needed.      simethicone (MYLICON) 80 mg chewable tablet Take 1 tablet (80 mg total) by mouth every 4 (four) hours as needed for Flatulence. (Patient not taking: Reported on 03/17/2019) 100 tablet 2     No current facility-administered medications for this visit.
A158	SectionSkipType T589 medications
T590	SectionSkip 6103 7342	1. Ill-defined right pectoralis soft tissue mass with internal calcifications: 1.2 x 2.4 cm (series 4 1 image 64) with a maximum SUV of 4.6.  2. Right subpectoral lymph node: 0.7 cm in short axis (series 4 1 image 69) with maximum SUV of 4.8.  3. Hypoenhancing caudate lobe lesion: 1.9 x 1.5 cm (series 4 1 image 29) with a maximum SUV of 16.1.   4. Lytic S1 vertebral body lesion: maximum SUV of 6.6.  Lymph nodes: Index nodes as described above. Additional hypermetabolic right internal mammary node is 0.6 x 0.8 cm (series 4 1 image 75 with a maximum SUV of 4.3.  The hypermetabolic caudate lobe lesion is markedly increased in size when compared to prior CT abdomen/pelvis from 09/29/2018. Additional hypoattenuating, hypermetabolic segment VII lesion is 1.3 x 1.7 x 1.5 cm  with a maximum SUV of 11.2  02/25/19 Liver biopsy: triple negative metastatic breast cancer      Vaginal bleeding 09/28/2018    DVT (deep venous thrombosis) (HCC) 08/31/2018     Left Subclavian DVT diagnosed 05/16/18. Dye study demonstrated complete occlusion of the brachiocephalic vein - now s/p Mediport removal on 08/04/18 on rivaroxaban 20mg PO daily.        Endometrial carcinoma (HCC) 08/26/2018     Added automatically from request for surgery *****
A290	SectionSkipType T590 radiology_report
T5	SectionSkip 12328 13301	PHYSICAL EXAM  ECOG 0  Vital Signs:  BP 116/75  | Pulse 75  | Temp 36.8 C (98.2 F) (Oral)  | Resp 16  | Ht 166 cm (5' 5.35") Comment: December 2018 | Wt 86.5 kg (190 lb 12.8 oz)  | LMP 06/22/2018  | SpO2 98%  | BMI 31.41 kg/m   Constitutional:  WDWN, NAD.  Skin: warm, moist. No rashes or lesions.  Eyes: sclera anicteric, PERRL, EOMI.   HENT: sinuses nontender, nasal mucosa intact, pharynx without erythema, no thrush.   Lymph Nodes: no cervical, supraclavicular, or axillary lymphadenopathy.    Respiratory: BL lungs CTA, resonant to percussion, no wheezes, rhonchi, or crackles  Cardiovascular: normal heart rate, normal rhythm, no murmurs, no edema  Breast: no masses  GI: bowel sounds normal, soft, nontender, no distention, no organomegaly   Musculoskeletal: no point tenderness over bones or joints   Neurologic: alert & oriented x 3, no focal motor or sensory deficits  Psychiatric: mood stable    RESULTS  I have personally reviewed and interpreted the following:
A337	SectionSkipType T5 physical_exam
T591	Tobacco 12024 12037	Former Smoker
A338	IsStoppedOrContinuing T591 stopped
T592	Drugs 12287 12300	Drug use: Yes
T593	Alcohol 12256 12282	Alcohol use: Not Currently
A339	IsStoppedOrContinuing T593 stopped
T594	Datetime 12145 12155	12/01/2017
R104	EndsOnOrAt Arg1:T591 Arg2:T594	
T595	Duration 12160 12165;12182 12185	Years 1.2
T596	ConsumptionQuantity 12042 12057	Packs/day: 1.00
R105	ConsumptionQuantityRel Arg1:T591 Arg2:T596	
T597	Duration 12062 12074	Years: 33.00
R106	HappensAtOnDuring Arg1:T591 Arg2:T597	
T598	SDoHModifier 12101 12118	Types: Cigarettes
T599	ConsumptionQuantity 12079 12096	Pack years: 33.00
R107	ConsumptionQuantityRel Arg1:T591 Arg2:T599	
R108	SDoHDesc Arg1:T591 Arg2:T598	
T600	SDoHModifier 12305 12321	Types: Marijuana
R109	SDoHDesc Arg1:T592 Arg2:T600	
T549	Datetime 5954 5964	April 2018
R102	BeginsOnOrAt Arg1:T550 Arg2:T549	
T601	Datetime 5967 5980	November 2018
R110	EndsOnOrAt Arg1:T550 Arg2:T601	
T602	Datetime 3133 3143	02/23/2019
T603	Allergy 14053 14059	zofran
A266	GenomicTestType T528 Germline
A342	GenomicTestType T529 Germline
A343	GenomicTestType T530 Germline
A344	GenomicTestType T531 Germline
A345	GenomicTestType T532 Germline
A346	GenomicTestType T533 Germline
A347	GenomicTestType T534 Germline
A348	GenomicTestType T535 Germline
A349	GenomicTestType T207 Germline
A350	GenomicTestType T547 Germline
A351	GenomicTestType T132 Germline
A352	GenomicTestType T148 Germline
A353	GenomicTestType T474 Germline
A354	GenomicTestType T475 Germline
T8	ClinicalCondition 233 246	breast cancer
A355	ChronicVal T8 non-chronic
A356	ContinuityVal T8 worsening
R1	TreatmentAdministeredForProblem Treatment:T9 Prob:T8	
R2	TreatmentAdministeredForProblem Treatment:T400 Prob:T8	
T604	DiagnosticLabTest 586 590	Labs
T605	LabTestResult 595 603	in range
A357	LabTestResultVal T605 normal
R111	ResultOfTest Desc:T605 Test:T604	
R112	InclusionCriteriaFor Arg1:T605 Arg2:T17	
T606	Frequency 752 762	3-4 months
R113	Temporal Arg1:T606 Arg2:T21	
T406	ClinicalCondition 1035 1041	cancer
A39	ChronicVal T406 non-chronic
A40	ContinuityVal T406 worsening
A359	TreatmentCategory T9 AntiNeoPlastics
A360	TreatmentIntentVal T12 palliative
T607	Age 909 911	44
T608	MedicationName 1199 1207	Prilosec
A362	TreatmentContinuityVal T608 continuing
A363	TreatmentTypeVal T608 others
A364	TreatmentCategory T608 Supportive
R114	TreatmentAdministeredForProblem Treatment:T608 Prob:T29	
T609	Duration 1304 1310	3 days
R115	BeginsOnOrAt Arg1:T609 Arg2:T412	
T610	MedicationName 1689 1696	xarelto
A366	TreatmentCategory T610 Others
A367	NegationModalityVal T610 affirmed
A368	TreatmentContinuityVal T610 finished
T611	ProcedureName 1716 1722	biopsy
A369	IntentVal T611 diagnosis
T612	ClinicalCondition 1738 1764	non-occlusive jugular clot
A370	ChronicVal T612 non-chronic
A371	ContinuityVal T612 stable
R116	TreatmentAdministeredForProblem Treatment:T610 Prob:T612	
T613	Datetime 3099 3109	02/23/2019
T614	ClinicalCondition 3084 3098	Lynch syndrome
A372	ChronicVal T614 chronic
A373	ContinuityVal T614 stable
A374	ExperiencerVal T614 patient
R117	BeginsOnOrAt Arg1:T614 Arg2:T613	
T615	ClinicalCondition 3120 3132	cancer (HCC)
A375	ChronicVal T615 chronic
A376	ContinuityVal T615 stable
R118	HappensAtOnDuring Arg1:T615 Arg2:T602	
T617	ClinicalCondition 3166 3178	cancer (HCC)
A377	ChronicVal T617 non-chronic
A378	ContinuityVal T617 worsening
R119	HappensAtOnDuring Arg1:T585 Arg2:T617	
T432	ClinicalCondition 3213 3219	cancer
R87	HappensAtOnDuring Arg1:T434 Arg2:T432	
T439	BiomarkerName 3296 3302	triple
A163	TreatmentTypeVal T445 neoadjuvant
A164	TreatmentIntentVal T445 curative
T126	ClinicalCondition 3597 3603	cancer
T618	ProcedureName 3738 3744	biopsy
A379	IntentVal T618 diagnosis
R120	TestOrProcedureConductedForProblem Test:T140 Prob:T139	
R121	ResultOfTest Desc:T467 Test:T140	
T146	BiomarkerName 4246 4250	MSH2
T147	BiomarkerName 4255 4259	MSH6
T619	BiomarkerResult 4230 4242	nuclear loss
A380	BiomarkerResultVal T619 Positive
R40	BiomarkerRel Arg1:T146 Arg2:T619	
R41	BiomarkerRel Arg1:T147 Arg2:T619	
R122	ResultOfTest Desc:T474 Test:T148	
T620	GenomicTest 4324 4344	Lynch syndrome panel
A381	GenomicTestType T620 Germline
T621	GenomicTestResult 4377 4382	EPCAM
A382	NegationModalityVal T621 negated
A383	GenomicTestType T621 Germline
T622	GenomicTestResult 4384 4388	MLH1
A384	NegationModalityVal T622 negated
T623	GenomicTestResult 4390 4394	MSH2
A385	NegationModalityVal T623 affirmed
T624	GenomicTestResult 4396 4400	MSH6
A386	NegationModalityVal T624 negated
T625	GenomicTestResult 4406 4410	PMS2
A387	NegationModalityVal T625 negated
R123	ResultOfTest Desc:T621 Test:T620	
R124	ResultOfTest Desc:T622 Test:T620	
R125	ResultOfTest Desc:T623 Test:T620	
R126	ResultOfTest Desc:T624 Test:T620	
R127	ResultOfTest Desc:T625 Test:T620	
R128	ResultOfTest Desc:T475 Test:T620	
T483	BiomarkerName 4611 4615	MSH2
T484	BiomarkerName 4617 4621	MSH6
T626	BiomarkerResult 4603 4607	loss
A388	BiomarkerResultVal T626 Positive
R47	BiomarkerRel Arg1:T483 Arg2:T626	
R48	BiomarkerRel Arg1:T484 Arg2:T626	
R129	ResultOfTest Desc:T528 Test:T587	
R130	ResultOfTest Desc:T529 Test:T587	
R131	ResultOfTest Desc:T530 Test:T587	
R132	ResultOfTest Desc:T531 Test:T587	
R133	ResultOfTest Desc:T532 Test:T587	
R134	ResultOfTest Desc:T533 Test:T587	
R135	ResultOfTest Desc:T534 Test:T587	
R136	ResultOfTest Desc:T535 Test:T587	
A389	GenomicTestType T542 Somatic
A390	GenomicTestType T541 Somatic
A391	NegationModalityVal T546 negated
T627	GenomicTest 5757 5777	Lynch syndrome panel
A392	GenomicTestType T627 Germline
T628	GenomicTestResult 5810 5815	EPCAM
A393	GenomicTestType T628 Germline
T629	GenomicTestResult 5817 5821	MLH1
A394	GenomicTestType T629 Germline
T630	GenomicTestResult 5823 5827	MSH2
A395	GenomicTestType T630 Germline
T631	GenomicTestResult 5829 5833	MSH6
A396	GenomicTestType T631 Germline
T632	GenomicTestResult 5839 5843	PMS2
A397	GenomicTestType T632 Germline
R137	ResultOfTest Desc:T207 Test:T627	
R138	ResultOfTest Desc:T547 Test:T627	
T633	Histology 5921 5940	well-differentiated
T634	Stage 5942 5948	FIGO 1
A398	HistoryVal T634 history
A399	EpisodeDescription T634 FirstOccurrence
T635	ClinicalCondition 10784 10790	Asthma
A400	ChronicVal T635 chronic
A401	ContinuityVal T635 stable
T636	ClinicalCondition 10832 10854	Bipolar disorder (HCC)
A402	ChronicVal T636 chronic
A403	ContinuityVal T636 stable
T637	ClinicalCondition 10860 10879	Breast cancer (HCC)
A404	ChronicVal T637 chronic
A405	ContinuityVal T637 stable
T638	ClinicalCondition 10885 10895	Depression
A406	ChronicVal T638 chronic
A407	ContinuityVal T638 stable
T639	ClinicalCondition 10901 10929	DVT (deep venous thrombosis)
A408	ChronicVal T639 chronic
A409	ContinuityVal T639 stable
T640	ClinicalCondition 10957 10968	Hepatitis C
A411	ContinuityVal T640 stopped
T641	Site 10942 10952	subclavian
T642	Laterality 10940 10941	L
R139	LateralityOfSite Arg1:T642 Arg2:T641	
R140	SiteOf Arg1:T641 Arg2:T639	
T643	ClinicalCondition 11027 11039	Hypertension
A410	ChronicVal T643 chronic
A412	ContinuityVal T643 stable
T644	ClinicalCondition 11217 11225	Leukemia
A413	ExperiencerVal T644 family
T645	ClinicalCondition 11340 11355	lacerated liver
A414	ExperiencerVal T645 family
T646	Age 11324 11327	40s
T647	Age 11331 11335	50s,
T648	ClinicalCondition 11599 11611	Colon cancer
A417	ExperiencerVal T648 family
T649	Age 11652 11655	40s
T650	Metastasis 11657 11661	mets
A419	ExperiencerVal T650 family
T651	Site 11665 11669	lung
R141	SiteOf Arg1:T651 Arg2:T650	
T559	ClinicalCondition 13465 13478	breast cancer
A278	ChronicVal T559 non-chronic
A279	ContinuityVal T559 worsening
R142	BeginsOnOrAt Arg1:T563 Arg2:T565	
T568	ClinicalCondition 13602 13615	breast cancer
A420	ChronicVal T568 non-chronic
A421	ContinuityVal T568 stable
T652	Site 13619 13627	axillary
R143	SiteOf Arg1:T652 Arg2:T567	
T653	Frequency 13711 13721	every week
T654	Frequency 13753 13766	every 3 weeks
R144	Temporal Arg1:T654 Arg2:T571	
R145	Temporal Arg1:T653 Arg2:T570	
T655	ProcedureName 13829 13833	port
A424	IntentVal T655 treatment-palliative
A425	TreatmentTypeVal T655 others
A426	TreatmentCategory T655 Others
T656	MedicationName 13897 13904	xarelto
A427	NegationModalityVal T656 affirmed
A428	TreatmentContinuityVal T656 planned
A429	TreatmentTypeVal T656 others
A430	TreatmentIntentVal T656 others
A431	TreatmentCategory T656 Others
R146	TreatmentAdministeredForProblem Treatment:T656 Prob:T365	
T657	ProcedureName 13915 13929	port placement
A432	IntentVal T657 treatment-palliative
A433	TreatmentTypeVal T657 others
A434	TreatmentCategory T657 Others
R147	ExclusionCriteriaFor Arg1:T656 Arg2:T657	
A435	TreatmentContinuityVal T577 continuing
A436	TreatmentTypeVal T577 others
A437	TreatmentIntentVal T577 others
A438	TreatmentContinuityVal T576 continuing
A439	TreatmentContinuityVal T573 continuing
A440	TreatmentIntentVal T573 palliative
A441	TreatmentContinuityVal T377 continuing
T658	MedicationName 14179 14188	mag oxide
A442	TreatmentContinuityVal T658 planned
A443	TreatmentIntentVal T658 others
A444	TreatmentCategory T658 Supportive
T659	TreatmentDosage 14189 14194	400mg
R148	TreatmentDesc Therapy:T659 Desc:T658	
T660	Frequency 14195 14198	qhs
R149	TreatmentDesc Therapy:T660 Desc:T658	
T661	Symptom 14202 14206	Pain
A445	IsPresentOnFirstCancerDiagnosis T661 unclear
A446	IsCausedByDiagnosedCancer T661 unclear
A447	ChronicVal T661 non-chronic
A448	ContinuityVal T661 stable
R150	TreatmentAdministeredForProblem Treatment:T580 Prob:T661	
T662	TreatmentDosage 14261 14265	15mg
R151	TreatmentDesc Therapy:T662 Desc:T580	
T663	Frequency 14266 14269	BID
R152	TreatmentDesc Therapy:T663 Desc:T580	
R153	TreatmentAdministeredForProblem Treatment:T581 Prob:T661	
T664	MedicationModifier 14281 14284	prn
R154	TreatmentDesc Therapy:T664 Desc:T581	
R155	TreatmentAdministeredForProblem Treatment:T582 Prob:T661	
R156	TumorDesc TumorDetails:T403 Desc:T404	
R157	TumorDesc TumorDetails:T407 Desc:T406	
T665	ClinicalCondition 4957 4961	cyst
A449	ChronicVal T665 chronic
A450	ContinuityVal T665 stable
T666	Site 4966 4978	hydrosalpinx
R158	SiteOf Arg1:T666 Arg2:T665	
R159	TestOrProcedureReveals Test:T494 Desc:T665	
R160	ResultOfTest Desc:T495 Test:T494	
R161	ResultOfTest Desc:T497 Test:T494	
A451	NegationModalityVal T32 affirmed
A452	TreatmentContinuityVal T32 continuing
A453	TreatmentContinuityVal T412 continuing
A454	NegationModalityVal T38 affirmed
A455	TreatmentContinuityVal T38 continuing
A456	NegationModalityVal T425 affirmed
A457	TreatmentContinuityVal T425 continuing
A458	NegationModalityVal T40 affirmed
A459	TreatmentContinuityVal T40 continuing
A460	TreatmentContinuityVal T441 finished
A461	TreatmentContinuityVal T571 continuing
A462	TreatmentContinuityVal T580 continuing
A463	TreatmentContinuityVal T581 continuing
A464	TreatmentContinuityVal T582 continuing
A465	TreatmentContinuityVal T583 continuing
T616	TreatmentType 14319 14333	stool softener
A466	TreatmentContinuityVal T616 continuing
A467	TreatmentTypeVal T616 others
A468	TreatmentIntentVal T616 others
A469	TreatmentContinuityVal T564 continuing
A470	TreatmentContinuityVal T578 continuing
T667	Age 13346 13348	44
R163	TumorDesc TumorDetails:T556 Desc:T557	
R164	TumorDesc TumorDetails:T558 Desc:T557	
R165	TumorDesc TumorDetails:T432 Desc:T433	
R166	TumorDesc TumorDetails:T435 Desc:T432	
R167	TumorDesc TumorDetails:T436 Desc:T432	
R168	TumorDesc TumorDetails:T437 Desc:T432	
R169	TumorDesc TumorDetails:T438 Desc:T432	
R170	TumorDesc TumorDetails:T439 Desc:T432	
R171	TumorDesc TumorDetails:T440 Desc:T432	
R172	TestOrProcedureReveals Test:T453 Desc:T455	
R173	TestOrProcedureReveals Test:T453 Desc:T456	
R174	SiteOf Arg1:T465 Arg2:T464	
R175	TestOrProcedureReveals Test:T453 Desc:T457	
T668	Site 4044 4051	distant
R176	SiteOf Arg1:T668 Arg2:T466	
R177	ResultOfTest Desc:T132 Test:T130	
T669	DiseaseState 3652 3662	recurrence
R178	TestOrProcedureReveals Test:T127 Desc:T669	
T670	Site 4718 4723	Brain
R179	SiteOf Arg1:T670 Arg2:T489	
R180	SiteOf Arg1:T670 Arg2:T490	
T671	Site 4858 4860;4863 4869	TV pelvic
R181	SiteOf Arg1:T671 Arg2:T494	
R182	ResultOfTest Desc:T492 Test:T170	
T672	Site 6069 6075	breast
R184	SiteOf Arg1:T672 Arg2:T552	
T673	Site 3732 3737	colon
R183	SiteOf Arg1:T673 Arg2:T618	
T674	Site 4546 4559	primary colon
R186	SiteOf Arg1:T674 Arg2:T482	
T675	Site 5545 5550	colon
R187	SiteOf Arg1:T675 Arg2:T537	
R188	TumorDesc TumorDetails:T405 Desc:T403	
T676	Site 3114 3119	Colon
R189	SiteOf Arg1:T676 Arg2:T615	
T677	Site 3159 3165	breast
T678	Metastasis 3148 3158	Metastatic
R190	TumorDesc TumorDetails:T678 Desc:T617	
R191	SiteOf Arg1:T677 Arg2:T617	
T679	Site 3206 3212	breast
R192	SiteOf Arg1:T679 Arg2:T432	
T680	Site 3590 3596	Breast
R193	SiteOf Arg1:T680 Arg2:T126	
T681	Site 3786 3792	pelvic
R194	SiteOf Arg1:T681 Arg2:T453	
T682	Site 3978 3983	Colon
R195	SiteOf Arg1:T682 Arg2:T139	
T683	Site 961 966	colon
R185	SiteOf Arg1:T683 Arg2:T404	
T684	Site 978 989	endometrial
R196	SiteOf Arg1:T684 Arg2:T405	
T685	Site 1028 1034	breast
R197	SiteOf Arg1:T685 Arg2:T406	
R198	TreatmentAdministeredForProblem Treatment:T12 Prob:T11	
T686	Frequency 1562 1565	prn
R162	Temporal Arg1:T40 Arg2:T686	
T687	BiomarkerResult 3303 3311	negative
A471	BiomarkerResultVal T687 Negative
R199	BiomarkerRel Arg1:T439 Arg2:T687	
R200	SiteOf Arg1:T505 Arg2:T513	
R201	SiteOf Arg1:T505 Arg2:T514	
R203	SiteOf Arg1:T505 Arg2:T507	
R202	SiteOf Arg1:T505 Arg2:T508	
R204	SiteOf Arg1:T505 Arg2:T509	
T688	Site 5361 5367	breast
R205	SiteOf Arg1:T688 Arg2:T524	
R206	TumorDesc TumorDetails:T553 Desc:T552	
R207	SiteOf Arg1:T551 Arg2:T553	
A472	DiseaseStateVal T11 progression-others
A473	DiseaseStateVal T19 progression-others
A474	DiseaseStateVal T121 progression-others
A475	DiseaseStateVal T448 progression-recurrence
A476	DiseaseStateVal T669 progression-recurrence
A477	DiseaseStateVal T517 progression-recurrence
R208	SizeOf Arg1:T455 Arg2:T462	
R209	SizeOf Arg1:T456 Arg2:T464	
R210	SizeOf Arg1:T457 Arg2:T458	
R211	SizeOf Arg1:T478 Arg2:T481	
T689	ap_start 13310 13320	ASSESSMENT
T690	ap_end 14401 14406	weeks
T691	hpi_start 183 193	Impression
T692	hpi_end 1760 1765	clot.
T693	TreatmentDosage 14075 14079	40mg
R212	TreatmentDesc Therapy:T693 Desc:T377	
T694	Frequency 14080 14082	qd
R213	Temporal Arg1:T694 Arg2:T377	
R214	HappensAtOnDuring Arg1:T503 Arg2:T504	
R215	HappensAtOnDuring Arg1:T503 Arg2:T507	
R217	HappensAtOnDuring Arg1:T503 Arg2:T513	
R216	HappensAtOnDuring Arg1:T503 Arg2:T514	
R218	HappensAtOnDuring Arg1:T503 Arg2:T508	
R219	HappensAtOnDuring Arg1:T503 Arg2:T509	
R221	HappensAtOnDuring Arg1:T516 Arg2:T524	
R220	HappensAtOnDuring Arg1:T516 Arg2:T518	
R222	HappensAtOnDuring Arg1:T516 Arg2:T519	
R223	HappensAtOnDuring Arg1:T516 Arg2:T520	
